Px Pulse

Px Pulse

Px Pulse explores vital topics confronting the field of HIV prevention research. Our monthly podcast will deepen your knowledge and help you “check the pulse” of this fast-paced field and the urgent challenges still ahead. Tune in for interviews, first-person accounts and robust discussion from advocates, researchers, policy-makers and community stakeholders as they take on critical issues facing HIV prevention research today.

  1. Critical Advocacy: How Civil Society is defending the HIV Response and Global Health

    MAY 13

    Critical Advocacy: How Civil Society is defending the HIV Response and Global Health

    The upending of US policy by the new presidential administration has collapsed the foundation for global health and the HIV response at every level, from research to program delivery.  It’s been a desperate scramble for everyone who cares the lives and wellbeing of those impacted by HIV. Wading into the chaos, all over the world are advocates who began organizing within days, even minutes—as soon as the US government federal executive orders started coming down.   Positive change depends on fierce and effective community leadership, and pressuring powerbrokers to do the right thing.)  Two veteran global health leaders from civil society talk about how civil society is responding. Amanda Banda is Strategic Advisor to the COMPASS Coalition and Asia Russell is Executive Director of Health Gap, and both are members of CHANGE, a coalition with more than 1,500 people, from organizations in nearly every continent, working in coordination to defend global health and the HIV response. https://avac.org/resource/critical-advocacy/ Key Resources Join weekly CHANGE calls, every Thursday 9 AM Washington DC | 4 PM Nairobi to get involved, send us an email for the link to join: contact.change.2025@gmail.com CHANGE resources to fight back against US government HIV and global health cuts and funding freezes, visit pepfarwatch.org/pepfar-funding-freeze Research Matters – Resources to Protect Research Funding  PxWire: May 2025 Despite USG Global Health Collapse, Here Are Several Data Trackers To Support Your Advocacy

    20 min
  2. Lenacapavir: The case for investing in delivering HIV prevention

    09/19/2024

    Lenacapavir: The case for investing in delivering HIV prevention

    The promise of long-acting PrEP has been super-charged this year by studies showing the powerful efficacy of an antiretroviral known as lenacapavir (LEN).  This episode of PxPulse goes deep on LEN for PrEP. Recorded just days before Gilead’s announcement that PURPOSE 2 also found very high efficacy, Dr. Flavia Kiweewa, a principal investigator of PURPOSE 1, the first trial to announce efficacy, lays out the research findings and what they mean. And Chilufya Kasanda Hampongo of Zambia’s Treatment Advocacy and Literacy Campaign and Mitchell Warren of AVAC talk about how to change a long history of squandered opportunities to get rollout right.  The PURPOSE1 trials announced findings in June that a twice-yearly injection of LEN was 100% effective among cisgender women, with zero new cases of HIV. And the PURPOSE 2 trial among cisgender men, and trans and non-binary people, was shown to reduce the risk of HIV by 96%.  LEN now enters a select category, one of five ARV-based options for PrEP that all protect against HIV if you take them.  But many of the people applauding the results from PURPOSE 1 and 2 will tell you that breakthrough science like this is, as hard as it is, is still the easy part. To break the back of the HIV epidemic demands overcoming an altogether different challenge—coordinating and accelerating every step in rolling out new products so that everyone who needs HIV prevention can get it.    Listen to this podcast to learn what must be done to finally deliver on the promise of highly effective HIV prevention, from pills to rings to injectable PrEP and beyond.   Resources  Second Pivotal Trial of Twice-Yearly HIV Prevention Injection Safe and Highly Effective: PURPOSE 2 Trial Among Gay Men, Trans and Nonbinary People, AVAC Press Release  The Lens on LEN: The basics on injectable lenacapavir as PrEP, AVAC  Country planning matrix, PrEPWatch  Moving a Product to the Real World, AVAC  The long wait for long-acting HIV prevention and treatment formulations, Lancet  A game-changer for PrEP if access is adequate, Lancet  Allocation of Non-Commercial CAB for PrEP Supply in Low- and Middle-Income Countries, 2023-2025, AVAC  Generic Cabotegravir Timelines, AVAC  UNAIDS Exec Summary, UNAIDS  Lenacapavir: What it would it take to get the 6-monthly anti-HIV jab to SA, Bhekisisa

    32 min

Ratings & Reviews

5
out of 5
10 Ratings

About

Px Pulse explores vital topics confronting the field of HIV prevention research. Our monthly podcast will deepen your knowledge and help you “check the pulse” of this fast-paced field and the urgent challenges still ahead. Tune in for interviews, first-person accounts and robust discussion from advocates, researchers, policy-makers and community stakeholders as they take on critical issues facing HIV prevention research today.

You Might Also Like